Latest News

Common multiple sclerosis drugs taken together do not reduce relapse risk

A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While findings suggest that taking both INF and GA together was not superior to GA monotherapy in reducing relapse risk; the combination therapy does appear to reduce new lesion activity and total lesion volume.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Air pollution linked to slower cognitive development in children

  • Creative genius driven by distraction

  • Republicans trust science -- except when it comes to health insurance and gay adoption

  • Alcohol screening, intervention for risky drinking: A guide for physicians

  • Anxious people more apt to make bad decisions amid uncertainty

  • Myelin-maker: How an FDA-approved drug boosts myelin synthesis

  • Vaccine skeptics aren't swayed by emotional scare tactics

  • Administering Sedatives for Patients Receiving General Anesthesia Questioned

  • Examination of prior authorization policies for antipsychotic prescribing to children

  • ADHD plus childhood trauma heightens risk for self-harm, suicide

  •